TC
GNMX

TFS Capital’s Aevi Genomic Medicine Inc GNMX Stock Holding History

TFS Capital’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-49,461
Closed -$92K – 849
2017
Q1 		$92K Buy
49,461
+5,839
+13% +$26.4K 0.03% 595
2016
Q4 		$226K Buy
+43,622
New +$230K 0.06% 484
2016
Q3 		– Sell
-47,802
Closed -$265K – 1108
2016
Q2 		$265K Buy
47,802
+32,139
+205% +$169K 0.05% 644
2016
Q1 		$69K Buy
+15,663
New +$64.5K 0.01% 932

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

TFS Capital's GNMX Position: Q2 2017 in Review

TFS Capital sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 49,461 shares — an estimated $92K sold.

TFS Capital first reported a position in GNMX in Q1 2016 and held it in 4 quarters. The position peaked at $265K in Q2 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • TFS Capital reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 49,461 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $92K.
  • TFS Capital first reported a position in Aevi Genomic Medicine Inc in Q1 2016 and held it in 4 quarters.
  • TFS Capital's Aevi Genomic Medicine Inc position peaked at $265K in Q2 2016.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.